ABIONYX Pharma SA (EPA:ABNX)

Market Cap	45.43M
Revenue (ttm)	4.86M
Net Income (ttm)	-3.36M
Shares Out	34.68M
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,391
Average Volume	43,392
Open	1.330
Previous Close	1.310
Day's Range	1.292 - 1.318
52-Week Range	0.910 - 1.500
Beta	0.09
RSI	62.55
Earnings Date	Mar 6, 2025

About ABIONYX Pharma

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteine...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 61
• Stock Exchange: Euronext Paris
• Ticker Symbol: ABNX

Financial Performance

In 2023, ABIONYX Pharma's revenue was 4.64 million, a decrease of -11.65% compared to the previous year's 5.25 million. Losses were -3.52 million, -16.36% less than in 2022.